At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 1,254 enrolled
Drug / intervention
Ubrogepant +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multicenter, Randomized, Open-Label Extension Study to Evaluate the Long-Term Safety and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine With or Without Aura
In Brief
A Phase 3 clinical trial evaluating Ubrogepant, Placebo-matching Ubrogepant, and 1 other intervention for Migraine, With or Without Aura. Completed, enrolled 1,254 participants across 177 sites.
Detailed Summary
This study will evaluate the long-term safety and tolerability of intermittent treatment with ubrogepant for the acute treatment of migraine over 1 year.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMigraine, With or Without Aura
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
2017201820192020202120222023202420252026
First PostedAug 2016
Enrollment StartSep 2016
Primary CompletionAug 2018
TodayJul 2026
First PostedAug 19, 2016
Enrollment StartSep 13, 2016
Primary CompletionAug 2, 2018
TodayJul 2, 2026
Enrollment to primary: 1.9 yearsPosted 9.9 years ago
Interventions
Ubrogepantdrug
Ubrogepant tablet(s) orally for the treatment of a qualifying migraine attack.
Placebo-matching Ubrogepantdrug
Ubrogepant placebo-matching tablet orally for the treatment of a qualifying migraine attack.
Usual Caredrug
Treatment for a migraine as prescribed by the physician as standard of care in clinical practice.